

+ DURAFIBER[◇] Absorbent Gelling Fibrous Dressing

DURAFIBER Dressing delivers high absorbency even under compression, and minimal shrinkage with the added advantage of easy, one-piece removal.¹⁻⁶




Smith+Nephew

DURAFIBER[◇]


Absorbent Gelling Fibrous Dressing

www.smith-nephew.com



DURAFIBER[®] Dressing is an absorbent gelling dressing indicated for the management of chronic and acute, full thickness, partial thickness, or shallow granulating exuding wounds¹


Mode of action



1. Before application



2. Forming a gel upon contact with exudate¹



3. Locking in exudate and harmful bacteria it may contain^{7,9}

Features and benefits



Pathogenic bacteria are absorbed into the dressing,⁷ and dead **space where bacteria may proliferate is reduced**^{5,8}



Absorbs pathogenic bacteria away from the wound once fluid is in the dressing^{7,9}



DURAFIBER Dressing **gels fast on contact with fluids**¹



DURAFIBER Dressing **becomes a soft gel in contact with fluid**^{1,2,10} with a high absorbency, providing effective fluid management¹⁻³



Minimal lateral absorption **minimises the risk of peri-wound maceration** and thus **helps to promote healthy surrounding skin**^{2,11}

Indications

- DURAFIBER Dressings are indicated for the management of chronic and acute, full thickness, partial thickness, or shallow granulating exuding wounds, including leg ulcers, pressure ulcers, diabetic ulcers, surgical wounds, donor sites, tunneling and fistulae wounds, and traumatic wounds
- DURAFIBER Dressing can be left in place for up to 7 days, dependent upon the wound type and levels of exudate present^{2,3,12}
- DURAFIBER Dressing can be used in conjunction with ALLEVYN[®] Foam Dressings, or PROFORE[®] Multi-layer Compression Bandage System^{13,14}

DURAFIBER Dressing

S+N Code	Size	Carton
66800559	5cm x 5cm	10
66800560	10cm x 10cm	10
66800551	10cm x 12cm	10
66800561	15cm x 15cm	5
66800546	4cm x 10cm	5
66800547	4cm x 20cm	5
66800548	4cm x 30cm	5
66800563	2cm x 45cm	5

Smith+Nephew, Kay Fiskers Plads 9, 2300 København S, Denmark T: +45 45 80 61 00
 Smith+Nephew, Krokslätts Fabriker 39, 431 37 Mölndal, Sweden T: +46 31 74 65 800
 Smith+Nephew, Snarøyveien 36, 1364 Fornebu, Norway T: +47 66 84 20 20
 Smith+Nephew, Lentäjantie 1, 01530 Vantaa, Finland T: +358 (0)207 866 333

◇Trademark of Smith+Nephew, All Trademarks acknowledged, ©2025 Smith+Nephew 47134-nord 04/25

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, warnings and precautions, please consult the product's Instructions for Use (IFU) prior to use.

References

- Smith+Nephew 2010. DURAFIBER Dressing Physical Properties. Internal report DS/10/056/R1.
- Barrett S, Callaghan R, Ivins N, Stephen-Haynes J. Case series evaluation: the use of Durafiber on exuding wounds. *Wounds*. 2012;8(3):104–113.
- Davies A, Harish S, Price J. Selecting dressings to manage exudate and enhance patient wellbeing. *Wounds UK*. 2015;11(3):54–61.
- Milne J, Grothier L. A clinical evaluation of DURAFIBER[™], a new generation of fibrous gelling dressings. Paper presented at: Wounds UK; 2011; Harrogate.
- Smith+Nephew 2011. Testing Performed as Part of DURAFIBER Photo-Shoot. Internal report DS/11/187/DOF.
- Smith+Nephew 2014. Testing of the absorption of DURAFIBER and Aquacel[™] while the dressing is under compression. Internal report DS/10/037/R1.
- Smith+Nephew 2010. Visual demonstration of sequestration of *Pseudomonas aeruginosa* and *Staphylococcus aureus* in a DURAFIBER dressing using confocal microscopy. Internal report 1004001.
- Smith+Nephew 2010. The potential for proliferation of bacteria in wound exudate. Internal report RR-WMP06290-40-01.
- Smith+Nephew 2023. Investigation of the bacterial retention capacity of ALLEVYN[®] Life, DURAMAX[®] S and DURAFIBER[®] dressings over a 1-hour test period against Methicillin-resistant *Staphylococcus aureus* (MRSA) and *Pseudomonas aeruginosa*. CSD.AWM.23.019.
- Smith+Nephew 2018. Volunteer Evaluation of Wound Care Dressing Product Features. Internal report AWM/AWC/001/v1.
- Smith+Nephew 2010. Report of Testing on lateral wicking of DURAFIBER versus Aquacel[™] and Kaltostat[™] dressings. Internal report DS/10/042/R1.
- Smith+Nephew 2012. Wound Model Testing of Durafiber with various secondary dressings. Internal report DS/12/314/R.
- Smith+Nephew 2013. Wound model testing of Aquacel Extra and DURAFIBER dressings using a flow rate modelling that of a moderately exuding wound. Internal report DS/13/039/R.
- Smith+Nephew 2022. DURAFIBER use with concurrent retentive dressing overview. Internal report RD/22/007.